Objective: Carotid endarterectomy (CEA) reduces stroke risk in selected patients. However, CEA risk profile may be different in older patients. We compared characteristics and outcomes of octogenarians and nonagenarians with those of younger patients.
an increasingly unfavorable cost-efficacy relationship for CEA in asymptomatic patients with increasing age of the patient. More recently, De Rango et al 3 compared mortality in a series of octogenarians undergoing carotid interventions with the expected stroke and mortality for age-and gender-matched samples of the Italian population and also concluded that there was no benefit in octogenarians primarily because of the more limited life expectancy. Our practice has been to discourage CEA in patients of advanced age (specifically $80 years in the absence of symptoms). However, this approach has not been uniform in the United States as is clearly demonstrated by the age range of patients undergoing CEA in the Society for Vascular Surgery Vascular Quality Initiative (VQI) registry. Furthermore, Cronenwett's paper was an economic modeling study and not a trial; it is now nearly 20 years old, and the assumptions on both the risk side and the cost side of the model may no longer be relevant. The VQI database now contains data from >50,000 CEAs. The power of this large database to allow detection of small differences in outcomes could have a significant impact on decision-making and resource use. We therefore sought to use this database to evaluate the hypothesis that there is no difference in outcome for older patients undergoing CEA compared with younger patients.
METHODS
A deidentified data set including all CEAs was obtained from the VQI national database. The CEA module of this database at the time our data set was received included 221 variables. These variables described characteristics of the patients; comorbidities; history of previous peripheral arterial, cardiac, or carotid interventions; cerebrovascular symptoms, if any; severity of carotid disease; method of determining severity of disease; contralateral disease; conduct of the surgery; early outcomes, including complications; and outcomes at late follow-up. We restricted our analysis to primary CEA, excluding second contralateral CEA in the same subject, combined CEA and coronary artery bypass, "redo" CEA, and CEA after carotid stenting. The data set was imported into the standard statistics platforms SPSS (IBM Corp, Armonk, NY) and SAS (SAS Institute, Cary, NC). We then defined our cohort of older patients as $80 years of age, consistent with prior studies, and compared them with a cohort of patients younger than 80 years to test our hypothesis that results after CEA are different in octogenarians and nonagenarians compared with younger patients. We compared characteristics and comorbidities of the patients in univariate models. We compared outcomes including periprocedural ipsilateral stroke, any periprocedural neurologic event, and periprocedural death. We compared survival of the patients using life-table methods. We also compared 1-year freedom from hemispheric ischemic events, restenosis, and reintervention.
Univariate comparisons were made at single time points (initial perioperative period and 1-year follow-up). The initial analyses were primarily examinations of simple 2 Â 2 contingency tables. Tests of hypothesis were made using Fisher exact test or c 2 test at each of the two time points. The size of the data set also allowed exploration of the impact of multiple other characteristics of the patients as possible predictors of outcome. Thus, if a difference in a patient characteristic (including comorbid conditions) was detected (the null hypothesis rejected) for any outcome, each of the available patient characteristics was entered individually into a logistic regression model with older or younger patient group as the other predictor variable for each of these outcomes. All covariates with P < .10 in the univariate models along with age group as the only other predictor variable were included in a logistic regression model with stepwise removal of covariates of P > .05 to explore whether characteristics of the patient other than the age group had predictive value with respect to the risk of adverse events. The list of possible covariates included age, gender, race, side of surgery, severity of stenosis, severity of contralateral stenosis, urgency of surgery, symptomatic status, use of a shunt, use of a patch (for conventional CEA), type of anesthesia, azotemia, comorbidities (such as dialysis dependence, diabetes mellitus, hypertension, dyslipidemia, smoking status, coronary artery disease [multiple variables], and congestive heart failure), and use of selected medications (eg, beta blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, statins, and dextran). The inclusion of information from the Social Security Death Index allowed examination of survival out to 10 years and more in this data set and also allowed Cox proportional hazards modeling to explore the possible impact of various patient factors other than age on survival.
The final research proposal was approved by the Institutional Review Board of Northwestern Medicine, West Region, on June 9, 2015. The study was exempted from requirement for review, and consent of the subject was waived because the study involved review of a preexisting deidentified data set.
RESULTS
Between 2003 and 2015, a total of 51,001 patients undergoing CEA had clinical data entered into the VQI database. Of these, 42,693 (84%) were primary CEAs with the exclusion criteria listed before. Of these, there were 7390 (17%) patients 80 years or older who underwent CEA. Octogenarian and nonagenarian patients were different from younger patients in some univariate comparisons (Table I) reflecting the effect of a nonrandomized comparison and a very large data set. However, clear exceptions were significantly greater rates of symptoms (any prior neurologic event), living other than at home, and urgent CEA in older patients. There were also significantly greater rates of current smoking and diabetes mellitus in younger patients.
There were also some differences in the conduct of CEA in the two groups (Table II) . Of note, the older patients were more likely to have undergone CEA using regional anesthesia. Other differences in conduct of CEA appear to be small and once again likely reflect the very large data set.
There were some outcome differences between groups (Table II) . There was a slightly greater neurologic complication rate in the older patients (any new ipsilateral neurologic event and any new ipsilateral stroke). There was also a slightly greater rate of perioperative myocardial infarction in the older patients. Older patients were more likely to be discharged to other than home.
Life-table comparisons of selected outcomes identified some differences as well (Table II) . The 30-day and 1-year point estimates of survival were slightly less for older than for younger patients. As expected, longer term survival was substantially less for older patients (Fig) . Freedom from ipsilateral cortical neurologic events was also slightly less in older than in younger patients, although once again, this life-table analysis included perioperative events that were already known to be slightly more common among the older patients. Given the small but significant differences between groups with respect to characteristics of the patients, comorbidities, and indications for surgery, we further explored the outcome differences with multivariate modeling using logistic regression and Cox proportional hazards models (Table III) . With respect to perioperative neurologic events (any new ipsilateral neurologic event and any new ipsilateral stroke), logistic regression results show that pre-CEA symptoms (any prior neurologic event and pre-CEA ipsilateral cortical ischemic event) and urgent or emergent procedures were significant independent predictors of these adverse outcomes. However, even after adjusting for these factors, odds ratios showed that risks were slightly but significantly greater for the older age group (ie, older age group remained a significant independent predictor of these adverse outcomes). Similarly, Cox proportional hazards modeling (once again including adverse outcome events in the 30-day perioperative period) indicated that any prior neurologic event, pre-CEA ipsilateral cortical ischemic event, and urgent or emergent procedure were significant independent predictors of these adverse outcomes at late follow-up but that older age group remained a significant independent predictor of these adverse outcomes.
Given the large data set and significant differences between groups of patients, we also performed a propensity score-adjusted analysis. Results after propensity score adjustment were different in that pre-CEA ipsilateral cortical ischemic event was no longer an independent predictor in the logistic regression and Cox proportional hazards models (Table III) . However, with respect to the variable of most interest (age group $80 vs <80 years), results were indistinguishable from those without propensity score adjustment (Table III) . We repeated the multivariate analyses using age as a continuous variable instead of grouping older vs younger (Table III) . In contrast to the comparison using age groups, comparison using age as a continuous variable found no independent predictive value of age with respect to early (logistic regression model odds ratio, 1.00) or late (Cox proportional hazards model hazard ratio, 1.00). The apparent discrepancy between age as a group and age as a continuous variable suggested a nonlinear relationship between age and neurologic risk for CEA, thus violating a key assumption of linear regression analysis. Therefore, we repeated our original analyses using age grouped by decades. This analysis found no difference with respect to any new ipsilateral neurologic event and any new ipsilateral stroke among the decades <80 years of age; but once again, age $80 years was associated with a slightly higher risk of these events, thus further supporting an apparent nonlinear relationship between age and risk of any new ipsilateral neurologic event and any new ipsilateral stroke (data not shown). We performed a separate life-table analysis of estimated mortality after separating symptomatic and asymptomatic patients (Table IV) . As one would expect, the 30-day and 1-year survival estimates were lower in the group of older patients. Inspection suggests that the numerical difference may have been slightly more significant at 1 year for the symptomatic group (Table IV) .
Because older patients were found to have a greater risk of discharge to other than home, we performed multivariate analysis to explore whether this greater risk could be explained by greater rates of certain comorbidities and operative detail differences between the groups. This analysis indicated that many variables, including comorbidities and a few operative details, appeared to account for part of the difference in discharge to other than home (Table V) . It is difficult to (Continued on next page) explain how some of these (eg, use of electroencephalographic monitoring) might have an impact on discharge disposition, but comorbidities such as congestive heart failure and the complication of perioperative myocardial infarction were associated with a greater rate of discharge to other than home. However, age group remained a significant predictor with a 2.5-fold greater rate of discharge to other than home in the group of older patients.
DISCUSSION
The landmark studies of CEA in both symptomatic and asymptomatic patients all excluded patients beyond a certain age. For example, both the North American Symptomatic Carotid Endarterectomy Trial (NASCET) and the Asymptomatic Carotid Artery Surgery (ACAS) trial initially excluded those older than 79 years, 4, 5 although NASCET later changed exclusion criteria and allowed older patients to enter the study. Patients 80 years and older have clearly been a significant part of many CEA practices outside of such studies. Several single-institution studies have explored the role of age in predicting outcomes for CEA. We reviewed those studies at the time of our previous publication 17 years ago, 6 and the consensus was that increasing age was not associated with increased risk of early complications, including stroke and death after CEA. A number of studies have explored this same topic and have been published since our original study. Despite editorials criticizing CEA in older patients, 7 with few exceptions 8, 9 the majority of the single-center published articles concluded that there was no significant outcome difference between older and younger patients undergoing CEA.
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Indeed, analysis of data from NASCET (all symptomatic patients) showed that the net benefit of CEA was actually greater in octogenarians because the risks in the surgical (CEA) arm were similar in younger and older patients, but the outcomes in the best medical treatment arm were significantly worse in octogenarians than in younger patients. 24 Better outcomes in the older patients in previous publications may simply reflect selection of patients with fewer comorbidities. 16 Analyses from administrative databases, probably not subject to publication bias as single-center studies may be, have often concluded that older patients suffer more complications than do younger patients and patients in prospective studies. 25, 26 However, some of the data contributing to these latter studies are now >20 years old and are not likely to reflect current results after CEA. Furthermore, as noted before, many of the precedent studies are single-institution studies. We proposed to take advantage of the very large VQI CEA data set as likely reflective of the community and more current results of CEA. Despite some concerns about data fidelity, reports from registries like the VQI and administrative databases would not be expected to be subject to "publication bias" as would single-institution studies. 27 This study found a slightly greater risk of adverse neurologic outcomes after CEA in older than in younger patients. However, the risk in both groups is low. Furthermore, the risks as reported in this and other more recent trials are substantially lower than in the landmark trials of CEA and we believe provide evidence that there is always room for further improvements. 28, 29 This is particularly true in symptomatic patients, who in the past suffered a substantially greater risk of adverse neurologic outcomes than did asymptomatic patients after CEA and who now enjoy a significantly lower risk compared with those in reports from 20 years ago. Furthermore, multivariate analysis in our study confirms that most of the difference in neurologic complication rates can be explained by the fact that CEA was performed more often for symptomatic disease and was performed urgently or emergently in older patients. In contrast to no increase or slight increase in neurologic complications with increasing age for CEA, the trials of carotid stenting have consistently shown a substantial increase in neurologic complications with increasing age using carotid artery stenting. [29] [30] [31] On the other hand, given the front-loaded risk of adverse neurologic events at the time of CEA, the benefit of CEA is dependent on survival of the patient. The general concept that age predicts life expectancy still applies as it did at the time of the study of Cronenwett et al. 2 Estimated mortality was greater in the older group both at 30 days and at 1 year, and this difference may have been slightly more pronounced among the symptomatic patients. However, given the apparent increase in risk of stroke with advancing age with best medical therapy, 24 apparent decline in adverse outcomes after CEA since the landmark studies were performed, and successful efforts to control resource use, CEA may now be economically favored at more advanced ages than was the case when the original analysis of Cronenwett et al was performed. However, the findings in the current study are further evidence that at least in asymptomatic patients, the treating physician should continue to consider declining life expectancy with advancing age when making treatment recommendations to patients with carotid atherosclerotic disease. Importantly, a consideration not always addressed in these studies but likely to be a significant factor is that asymptomatic octogenarians and nonagenarians with anatomically severe carotid disease may not be appropriate for any intervention. 32 The apparent discrepancy in multivariate models between age as a grouping variable and age as a continuous variable (ie, that age group predicts a small but highly significant difference in neurologic outcome, whereas age as a continuous variable is not a predictor of neurologic outcome) is truly fascinating. We believe that a likely explanation for this is that the relationship between age and adverse neurologic outcome is probably not linear, thus violating the basic assumptions of both logistic regression and Cox proportional hazards models. Analysis using grouping by decade confirmed that risk of any new ipsilateral neurologic event and any new ipsilateral stroke was indistinguishable among groups in decades of age <80 years but that once again, age $80 years had a slightly greater risk of these events, supporting the likely nonlinear relationship between age and these adverse neurologic events. We also observed that the older patients were more likely to be discharged to other than their living situation before CEA, implying discharge to a skilled nursing facility or acute rehabilitation facility. Our multivariate analysis indicated that even if several other possible confounding variables were included in the model, age group remained a significant predictor of discharge to other than home. Given the extremely low risk of neurologic complications overall, it is difficult to explain a higher rate of discharge to other than the pre-CEA living situation because of neurologic complications of CEA. Although costs associated with rehabilitation and long-term care related to stroke in medical and surgical treatment for carotid disease have been considered in previous publications, we are not aware that the more general issue of rehabilitation and long-term care has been explored in economic modeling of CEA independent of neurologic complications of different treatment strategies. Given the clear improvement in outcomes after CEA and improvements in the outcomes with best medical therapy for extracranial atherosclerotic cerebrovascular disease since the legacy trials and especially the apparent less favorable outcome for best medical therapy in older patients in the NASCET trial, 24 it seems appropriate to perform new trials to explore the results with best medical therapy across the age spectrum (no exclusion based on age) and to perform new studies of economic models with these new data.
Limitations. This study was a nonrandomized retrospective analysis of prospectively collected data. It is possible that selection of patients and the fraction of older patients and the selection of those patients vary significantly across VQI participating centers, and there is an increased risk that the two study samples are different (ie, that any differences in outcomes may be due at least in part to differences in patient samples other than age). The VQI data set is presently focused on 1-year follow-up, and achieving complete follow-up even at 1 year has been a challenge in the VQI registry. Furthermore, the stroke, mortality, and major adverse event rate is so low in most CEA studies that it may be difficult to identify a difference in end points between older and younger patients. However, the size of the VQI data set provides a high level of confidence that a true difference of any magnitude would likely be detected. Sample size modeling was not performed because the precedent literature is likely subject to publication bias, and there is no legitimate way to predict any possible outcome differences. However, the size of the data set combined with the ability to adjust for multiple characteristics of the patient using multivariate models reduces the risk of both type I and type II errors. Finally, this study, like others evaluating CEA, does not have a cohort of patients undergoing optimal medical management. This prevents evaluation of the important comparison of intervention vs no intervention in this population of patients.
CONCLUSIONS
CEA continues to be a low-risk approach to treat severe carotid bifurcation atherosclerosis. The risk of adverse neurologic events appears to be slightly greater in octogenarians and nonagenarians after adjusting for characteristics of the patients as assessed in a large registry that likely reflects the general experience with CEA in North America better than do single-center or prospective randomized trials. However, the absolute risk of adverse events is low and better than in the landmark trials of >20 years ago. Age must be a consideration in making recommendations to patients with high-grade extracranial carotid disease, in particular because the benefit of CEA is dependent on age expectancy and older age predicts shorter life expectancy. Furthermore, the relationship between age and neurologic risk for CEA may not be linear, and there may be a threshold age above which risk can be expected to be greater. However, it is clear that CEA should be considered in intellectually intact independent older patients with high-grade extracranial carotid disease and who appear to have significant residual life expectancy. New prospective studies are necessary to better calibrate assumptions in economic modeling, quality of life, and other comparisons to better understand the role of age in decision-making with respect to CEA in older patients. 
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